



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/715 // (A61K 31/715, 31:57)</b>		A1	(11) International Publication Number: <b>WO 99/01142</b> (43) International Publication Date: <b>14 January 1999 (14.01.99)</b>
(21) International Application Number: <b>PCT/CA98/00649</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>3 July 1998 (03.07.98)</b>			
(30) Priority Data: <b>2,208,916 3 July 1997 (03.07.97) CA</b>			
(71) Applicant ( <i>for all designated States except US</i> ): <b>HYAL PHARMACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA)</b>		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and			
(75) Inventors/Applicants ( <i>for US only</i> ): <b>SEED, Michael, P. [GB/GB]; The Medical College of St. Bartholomew's Hospital, Charterhouse Square, London EC1M 6BQ (GB). ALAM, Chandan [GB/GB]; The Medical College of St. Bartholomew's Hospital, Charterhouse Square, London EC1M 6BQ (GB). WILLOUGHBY, Derek, A. [GB/GB]; The Medical College of St. Bartholomew's Hospital, Charterhouse Square, London EC1M 6BQ (GB).</b>			
(74) Agent: <b>HUGHES, ETIGSON; Suite 200, 175 Commerce Valley Drive West, Thornhill, Ontario L3T 7P6 (CA)</b>			
(54) Title: <b>PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANGIOSTATIC STEROID COMBINED WITH A HYALURONAN</b>			
(57) Abstract			
<p>A pharmaceutical composition utilized for increasing neovascularization and angiogenesis during wound healing in a mammal beyond the level of neovascularization and angiogenesis which would occur at the wound site without any treatment, said composition comprising an effective amount of any angiostatic steroid which has reduced or no deteriorative or detrimental side effects combined with an effective amount of a form of hyaluronan such as hyaluronic acid and pharmaceutically acceptable salts thereof.</p>			